{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T21:08:28Z","timestamp":1788815308944,"version":"build-2803163510"},"reference-count":62,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Psychiatry Research"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.psychres.2026.117400","type":"journal-article","created":{"date-parts":[[2026,8,16]],"date-time":"2026-08-16T21:57:33Z","timestamp":1786917453000},"page":"117400","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Comparative effectiveness of olanzapine and risperidone on clinical outcomes of schizophrenia in a low-income country"],"prefix":"10.1016","volume":"365","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-7945-2658","authenticated-orcid":false,"given":"Zemene","family":"Yiglet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Getasew","family":"Kibralew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hilina","family":"Tadesse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Worknew","family":"Molla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeneneh","family":"Workie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Digafe","family":"Demelash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diemesew","family":"Getnet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mulu","family":"Getnet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Setegn","family":"Fentahun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gebresilassie","family":"Tadesse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wondale","family":"Endeshaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mulualem","family":"Kelebie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.psychres.2026.117400_bib0001","doi-asserted-by":"crossref","first-page":"74","DOI":"10.5498\/wjp.v2.i5.74","article-title":"Medication adherence in schizophrenia","volume":"2","author":"Acosta","year":"2012","journal-title":"World J. Psychiatry"},{"issue":"11","key":"10.1016\/j.psychres.2026.117400_bib0002","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1176\/ajp.156.11.1686","article-title":"Antipsychotic-induced weight gain: a comprehensive research synthesis","volume":"156","author":"Allison","year":"1999","journal-title":"Am. J. Psychiatry"},{"issue":"20","key":"10.1016\/j.psychres.2026.117400_bib0003","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects","volume":"310","author":"Association","year":"2013","journal-title":"J. Am. Med. Assoc."},{"issue":"2","key":"10.1016\/j.psychres.2026.117400_bib0005","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/0893-133X(95)00069-P","article-title":"Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial","volume":"14","author":"Beasley","year":"1996","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"10.1016\/j.psychres.2026.117400_bib0004","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/BF02245617","article-title":"Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial","volume":"124","author":"Beasley","year":"1996","journal-title":"Psychopharmacology"},{"issue":"6","key":"10.1016\/j.psychres.2026.117400_bib0006","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1111\/j.1365-2753.2007.00921.x","article-title":"The validity of the CGI severity and improvement scales as measures of clinical effectiveness suitable for routine clinical use","volume":"14","author":"Berk","year":"2008","journal-title":"J. Eval. Clin. Pract."},{"issue":"5","key":"10.1016\/j.psychres.2026.117400_bib0007","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.1007\/s12325-021-01689-8","article-title":"Real-world data on the adverse metabolic effects of second-generation antipsychotics and their potential determinants in adult patients: a systematic review of population-based studies","volume":"38","author":"Bernardo","year":"2021","journal-title":"Adv. Ther."},{"issue":"1","key":"10.1016\/j.psychres.2026.117400_bib0008","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1186\/s12888-025-06759-7","article-title":"Relapse and associated factors among psychiatric patients in Africa: a systematic review and meta-analysis","volume":"25","author":"Birhan","year":"2025","journal-title":"BMC Psychiatry"},{"issue":"6","key":"10.1016\/j.psychres.2026.117400_bib0009","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1093\/schbul\/sby058","article-title":"Global epidemiology and burden of schizophrenia: findings from the global burden of disease study 2016","volume":"44","author":"Charlson","year":"2018","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.psychres.2026.117400_bib0010","first-page":"25","article-title":"A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients","author":"Chouinard","year":"1993","journal-title":"LWW"},{"issue":"5","key":"10.1016\/j.psychres.2026.117400_bib0011","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1176\/appi.ajp.158.5.765","article-title":"A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder","volume":"158","author":"Conley","year":"2001","journal-title":"Am. J. Psychiatry"},{"issue":"2","key":"10.1016\/j.psychres.2026.117400_bib0012","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1002\/wps.20420","article-title":"Prevalence, incidence and mortality from cardiovascular disease in patients with pooled and specific severe mental illness: a large-scale meta-analysis of 3211,768 patients and 113,383,368 controls","volume":"16","author":"Correll","year":"2017","journal-title":"World Psychiatry"},{"key":"10.1016\/j.psychres.2026.117400_bib0013","article-title":"Prevalence, incidence and mortality from cardiovascular disease in patients with pooled and specific severe mental illness: a large-scale meta-analysis of 3211,768 patients and 113,383,368 controls","author":"Correll","year":"2018","journal-title":"Correction"},{"issue":"1","key":"10.1016\/j.psychres.2026.117400_bib0015","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/j.2051-5545.2009.tb00199.x","article-title":"Metabolic syndrome in people with schizophrenia: a review","volume":"8","author":"De Hert","year":"2009","journal-title":"World Psychiatry"},{"issue":"2","key":"10.1016\/j.psychres.2026.117400_bib0014","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1038\/nrendo.2011.156","article-title":"Metabolic and cardiovascular adverse effects associated with antipsychotic drugs","volume":"8","author":"De Hert","year":"2012","journal-title":"Nat. Rev. Endocrinol."},{"issue":"9802","key":"10.1016\/j.psychres.2026.117400_bib0016","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1016\/S0140-6736(11)60891-X","article-title":"Scale up of services for mental health in low-income and middle-income countries","volume":"378","author":"Eaton","year":"2011","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.psychres.2026.117400_bib0017","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/1471-244X-13-50","article-title":"The nature of relapse in schizophrenia","volume":"13","author":"Emsley","year":"2013","journal-title":"BMC Psychiatry"},{"issue":"4","key":"10.1016\/j.psychres.2026.117400_bib0018","doi-asserted-by":"crossref","first-page":"521","DOI":"10.21767\/1791-809X.1000520","article-title":"Prevalence of antipsychotic drug non adherence and associated factors among patients with schizophrenia attending at Amanuel Mental Specialized Hospital, Addis Ababa, Ethiopia: institutional based cross sectional study","volume":"11","author":"Girma","year":"2017","journal-title":"Health Sci. J."},{"key":"10.1016\/j.psychres.2026.117400_bib0019","doi-asserted-by":"crossref","first-page":"43","DOI":"10.2147\/PROM.S42735","article-title":"Nonadherence with antipsychotic medication in schizophrenia: challenges and management strategies","author":"Haddad","year":"2014","journal-title":"Patient. Relat. Outcome Meas."},{"issue":"10202","key":"10.1016\/j.psychres.2026.117400_bib0020","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S0140-6736(19)31135-3","article-title":"Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis","volume":"394","author":"Huhn","year":"2019","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.psychres.2026.117400_bib0021","article-title":"Risperidone versus olanzapine for schizophrenia","author":"Jayaram","year":"2006","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.psychres.2026.117400_bib0022","article-title":"Second-generation (Atypical) antipsychotics and metabolic effects","volume":"19","author":"John","year":"2005","journal-title":"CNS Drugs"},{"issue":"9618","key":"10.1016\/j.psychres.2026.117400_bib0023","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/S0140-6736(08)60486-9","article-title":"Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial","volume":"371","author":"Kahn","year":"2008","journal-title":"Lancet"},{"issue":"suppl 1","key":"10.1016\/j.psychres.2026.117400_bib0024","doi-asserted-by":"crossref","first-page":"9708","DOI":"10.4088\/JCP.10075su1.00","article-title":"Introduction: recent advances in treatments for schizophrenia","volume":"72","author":"Kane","year":"2011","journal-title":"J. Clin. Psychiatry"},{"issue":"1","key":"10.1016\/j.psychres.2026.117400_bib0025","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1146\/annurev.med.52.1.503","article-title":"Atypical antipsychotics: new directions and new challenges in the treatment of schizophrenia","volume":"52","author":"Kapur","year":"2001","journal-title":"Annu. Rev. Med."},{"issue":"3","key":"10.1016\/j.psychres.2026.117400_bib0026","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1176\/appi.ajp.158.3.360","article-title":"Does fast dissociation from the dopamine D2 receptor explain the action of atypical antipsychotics?: A new hypothesis","volume":"158","author":"Kapur","year":"2001","journal-title":"Am. J. Psychiatry"},{"issue":"4","key":"10.1016\/j.psychres.2026.117400_bib0027","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1176\/appi.ajp.157.4.514","article-title":"Relationship between dopamine D2 occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia","volume":"157","author":"Kapur","year":"2000","journal-title":"Am. J. Psychiatry"},{"issue":"6","key":"10.1016\/j.psychres.2026.117400_bib0028","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1001\/archpsyc.64.6.633","article-title":"Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial","volume":"64","author":"Keefe","year":"2007","journal-title":"Arch. Gen. Psychiatry"},{"issue":"9","key":"10.1016\/j.psychres.2026.117400_bib0029","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1176\/appi.ajp.2020.177901","article-title":"The American Psychiatric Association practice guideline for the treatment of patients with schizophrenia","volume":"177","author":"Keepers","year":"2020","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.psychres.2026.117400_bib0030","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.g1173","article-title":"Management of psychosis and schizophrenia in adults: summary of updated NICE guidance","volume":"348","author":"Kuipers","year":"2014","journal-title":"BMJ"},{"key":"10.1016\/j.psychres.2026.117400_bib0031","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.psychres.2017.02.066","article-title":"Risperidone versus olanzapine in the acute treatment of Persistent Delusional Disorder: a retrospective analysis","volume":"253","author":"Kulkarni","year":"2017","journal-title":"Psychiatry Res."},{"issue":"9657","key":"10.1016\/j.psychres.2026.117400_bib0034","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(08)61764-X","article-title":"Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis","volume":"373","author":"Leucht","year":"2009","journal-title":"Lancet"},{"issue":"9896","key":"10.1016\/j.psychres.2026.117400_bib0033","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","article-title":"Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis","volume":"382","author":"Leucht","year":"2013","journal-title":"The Lancet"},{"issue":"9896","key":"10.1016\/j.psychres.2026.117400_bib0032","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","article-title":"Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis","volume":"382","author":"Leucht","year":"2013","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.psychres.2026.117400_bib0036","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia","volume":"353","author":"Lieberman","year":"2005","journal-title":"N. Engl. J. Med."},{"issue":"02","key":"10.1016\/j.psychres.2026.117400_bib0035","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.0207e04","article-title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia","volume":"68","author":"Lieberman","year":"2007","journal-title":"J. Clin. Psychiatry"},{"issue":"4","key":"10.1016\/j.psychres.2026.117400_bib0037","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/S2215-0366(18)30060-9","article-title":"Social determinants of mental disorders and the Sustainable Development Goals: a systematic review of reviews","volume":"5","author":"Lund","year":"2018","journal-title":"Lancet Psychiatry"},{"issue":"1\u20133","key":"10.1016\/j.psychres.2026.117400_bib0038","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.schres.2010.10.024","article-title":"Clinical Global Impression of Improvement (CGI-I) as a valid proxy measure for remission in schizophrenia: analyses of ziprasidone clinical study data","volume":"126","author":"Masand","year":"2011","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.psychres.2026.117400_bib0039","doi-asserted-by":"crossref","unstructured":"McDonagh MS ,Dana T,Selph,Devine EB, Cantor A, bougatsos C, et al.Treatments for schizophrenia in adults :a systematic review.Comparative Effectiveness Review No.198.Rockville(MD): Agency for Healthcare Research and Quality;2017 Oct.AHRQ publication No.17(18)-EHC031-EF.","DOI":"10.23970\/AHRQEPCCER198"},{"issue":"1","key":"10.1016\/j.psychres.2026.117400_bib0040","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s12891-025-08306-7","article-title":"Kinesiophobia and associated factors among people with musculoskeletal disorders in Ethiopia: a multicenter cross-sectional study","volume":"26","author":"Mekonnen","year":"2025","journal-title":"BMC Musculoskelet. Disord."},{"issue":"1","key":"10.1016\/j.psychres.2026.117400_bib0041","doi-asserted-by":"crossref","first-page":"S106","DOI":"10.1038\/sj.npp.1395370","article-title":"The role of serotonin in antipsychotic drug action","volume":"21","author":"Meltzer","year":"1999","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"10.1016\/j.psychres.2026.117400_bib0042","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/sj.mp.4001556","article-title":"Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs","volume":"10","author":"Miyamoto","year":"2005","journal-title":"Mol. Psychiatry"},{"issue":"1","key":"10.1016\/j.psychres.2026.117400_bib0043","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1080\/13651500510014783","article-title":"A comparison of olanzapine versus risperidone for the treatment of schizophrenia: a meta-analysis of randomised clinical trials","volume":"9","author":"Mudge","year":"2005","journal-title":"Int. J. Psychiatry Clin. Pract."},{"issue":"4","key":"10.1016\/j.psychres.2026.117400_bib0044","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1001\/archpsyc.59.4.337","article-title":"Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia","volume":"59","author":"Newcomer","year":"2002","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.psychres.2026.117400_bib0045","series-title":"The Pocket Guide to the DSM-5-TR\u2122 Diagnostic Exam","author":"Nussbaum","year":"2022"},{"key":"10.1016\/j.psychres.2026.117400_bib0046","series-title":"Management of Physical Health Conditions in Adults with Severe Mental Disorders","author":"Organization","year":"2018"},{"key":"10.1016\/j.psychres.2026.117400_bib0047","first-page":"25","article-title":"Adherence to antipsychotic medications","volume":"60","author":"Perkins","year":"1999","journal-title":"J. Clinic. Psychiatry"},{"issue":"5","key":"10.1016\/j.psychres.2026.117400_bib0048","first-page":"421","article-title":"The effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive review","volume":"28","author":"Peuskens","year":"2014","journal-title":"CNS Drugs"},{"issue":"6","key":"10.1016\/j.psychres.2026.117400_bib0049","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1192\/bjp.166.6.712","article-title":"Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol","volume":"166","author":"Peuskens","year":"1995","journal-title":"Br. J. Psychiatry"},{"issue":"1","key":"10.1016\/j.psychres.2026.117400_bib0050","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S2215-0366(19)30416-X","article-title":"Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis","volume":"7","author":"Pillinger","year":"2020","journal-title":"Lancet Psychiatry"},{"issue":"5","key":"10.1016\/j.psychres.2026.117400_bib0051","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1093\/schbul\/sbq083","article-title":"Antipsychotic dosing: how much but also how often?","volume":"36","author":"Remington","year":"2010","journal-title":"Schizophr. Bull."},{"issue":"2\u20133","key":"10.1016\/j.psychres.2026.117400_bib0052","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.schres.2010.07.012","article-title":"Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis","volume":"123","author":"Rummel-Kluge","year":"2010","journal-title":"Schizophr. Res."},{"issue":"S1","key":"10.1016\/j.psychres.2026.117400_bib0053","doi-asserted-by":"crossref","DOI":"10.1192\/bjo.2021.315","article-title":"Monitoring side-effects of antipsychotics using the glasgow antipsychotic side-effect scale","volume":"7","author":"Sterritt","year":"2021","journal-title":"BJPsych Open"},{"issue":"5","key":"10.1016\/j.psychres.2026.117400_bib0054","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1177\/0004867415608244","article-title":"Antipsychotic medication side effect assessment tools: a systematic review","volume":"50","author":"Stomski","year":"2016","journal-title":"Austral. New Zeal. J. Psychiatry"},{"issue":"1","key":"10.1016\/j.psychres.2026.117400_bib0055","doi-asserted-by":"crossref","first-page":"11","DOI":"10.22219\/sm.Vol20.SMUMM1.33729","article-title":"Validity and reliability of Mars-10 questionnaire on antipsychotic adherence In schizophrenia patients","volume":"20","author":"Syifa","year":"2024","journal-title":"Saintika Med."},{"issue":"3","key":"10.1016\/j.psychres.2026.117400_bib0056","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S0920-9964(99)00130-9","article-title":"Reliability and validity of a new Medication Adherence rating scale (MARS) for the psychoses","volume":"42","author":"Thompson","year":"2000","journal-title":"Schizophr. Res."},{"issue":"2","key":"10.1016\/j.psychres.2026.117400_bib0057","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1192\/bjp.bp.116.188078","article-title":"Undertreatment of people with major depressive disorder in 21 countries","volume":"210","author":"Thornicroft","year":"2017","journal-title":"Br. J. Psychiatry"},{"issue":"7","key":"10.1016\/j.psychres.2026.117400_bib0058","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1001\/jamapsychiatry.2017.1322","article-title":"Real-world effectiveness of antipsychotic treatments in a nationwide cohort of 29 823 patients with schizophrenia","volume":"74","author":"Tiihonen","year":"2017","journal-title":"JAMA Psychiatry"},{"issue":"7","key":"10.1016\/j.psychres.2026.117400_bib0059","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1176\/appi.ajp.160.7.1263","article-title":"Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: a 47-week study","volume":"160","author":"Tohen","year":"2003","journal-title":"Am. J. Psychiatry"},{"issue":"5","key":"10.1016\/j.psychres.2026.117400_bib0060","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1097\/00004714-199710000-00010","article-title":"Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders","volume":"17","author":"Tran","year":"1997","journal-title":"J. Clin. Psychopharmacol."},{"issue":"9690","key":"10.1016\/j.psychres.2026.117400_bib0061","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/S0140-6736(09)60995-8","article-title":"Schizophrenia","volume":"374","author":"Van Os","year":"2009","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.psychres.2026.117400_bib0062","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1001\/archpsyc.1981.01780270073010","article-title":"Subjective response to antipsychotic drugs","volume":"38","author":"Van Putten","year":"1981","journal-title":"Arch. Gen. Psychiatry"}],"container-title":["Psychiatry Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165178126004609?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165178126004609?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T20:22:58Z","timestamp":1788812578000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165178126004609"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":62,"alternative-id":["S0165178126004609"],"URL":"https:\/\/doi.org\/10.1016\/j.psychres.2026.117400","relation":{},"ISSN":["0165-1781"],"issn-type":[{"value":"0165-1781","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative effectiveness of olanzapine and risperidone on clinical outcomes of schizophrenia in a low-income country","name":"articletitle","label":"Article Title"},{"value":"Psychiatry Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.psychres.2026.117400","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117400"}}